Nextage Therapeutics (XTAE:NXTG) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:NXTG Nextage Therapeutics Ltd XTAE:NXTG
8 GF Score
Price ₪0.39
GF Value ₪0.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nextage Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XTAE:NXTG vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextage Therapeutics Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's Short Interest falls into.


XTAE:NXTG
8GF Score
Nextage Therapeutics Ltd XTAE:NXTG
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?

Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued. The current stock price of ₪0.39 is trading 25.8% above its estimated GF Value™ of ₪0.31. GuruFocus considers Nextage Therapeutics to be Modestly Overvalued.

Key valuation signals for XTAE:NXTG:

  • Short Interest:
  • GF Value™: ₪0.31 vs. price of ₪0.39 (25.8% above fair value)
  • GF Score™: 8/100 with 4 warning signs

No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nextage Therapeutics Business Description

Address Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
8GF Score

Get the complete analysis for XTAE:NXTG

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.39
Price
₪0.31
GF Value